GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getein Biotech Inc (SHSE:603387) » Definitions » EV-to-Revenue

Getein Biotech (SHSE:603387) EV-to-Revenue : 3.28 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Getein Biotech EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Getein Biotech's enterprise value is ¥4,287 Mil. Getein Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,306 Mil. Therefore, Getein Biotech's EV-to-Revenue for today is 3.28.

The historical rank and industry rank for Getein Biotech's EV-to-Revenue or its related term are showing as below:

SHSE:603387' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.75   Med: 6.02   Max: 20.61
Current: 3.28

During the past 12 years, the highest EV-to-Revenue of Getein Biotech was 20.61. The lowest was 2.75. And the median was 6.02.

SHSE:603387's EV-to-Revenue is ranked worse than
50.42% of 831 companies
in the Medical Devices & Instruments industry
Industry Median: 3.26 vs SHSE:603387: 3.28

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-27), Getein Biotech's stock price is ¥8.96. Getein Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2.57. Therefore, Getein Biotech's PS Ratio for today is 3.49.


Getein Biotech EV-to-Revenue Historical Data

The historical data trend for Getein Biotech's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getein Biotech EV-to-Revenue Chart

Getein Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.19 7.18 4.55 3.27 4.01

Getein Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.95 4.16 3.93 4.01 3.48

Competitive Comparison of Getein Biotech's EV-to-Revenue

For the Medical Devices subindustry, Getein Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Getein Biotech's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Getein Biotech's EV-to-Revenue falls into.



Getein Biotech EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Getein Biotech's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4286.960/1306.429
=3.28

Getein Biotech's current Enterprise Value is ¥4,287 Mil.
Getein Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,306 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Getein Biotech  (SHSE:603387) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Getein Biotech's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=8.96/2.569
=3.49

Getein Biotech's share price for today is ¥8.96.
Getein Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2.57.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Getein Biotech EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Getein Biotech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Getein Biotech (SHSE:603387) Business Description

Traded in Other Exchanges
N/A
Address
No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
Executives
Su En Kui Director
Yan Bin Director
Kong Ting Ting Director
Xu Xing De Director
Su En Ben Director

Getein Biotech (SHSE:603387) Headlines

No Headlines